GREY:ATBPF - Post by User
Post by
MrMugsyon Oct 12, 2022 10:22pm
275 Views
Post# 35021268
Outstanding Items ...
Outstanding Items ...With 346 direction set - improved formulation, faster onset of action, lower dose ... with increased therapeutic benefit and greater commercial potential, here's the further confusion on other expected items ...
1. Closing of CITA at anytime .
2. Commerical study - was expecting today but now it may be delayed. Does that mean it needs to be redone based on the realities of the improved formulation ? More details required here.
3. 352 update - I think this update was slated for November and was closely tied to OTENA. Now with the improved formulation, does that further delay a 352 update? Can OTENA do what 352 was supposed to do? More details required here as well.
4. IBD update - slated for Q4. Assuming it is unrelated to OTENA and 352. Therefore, a Nov/Dec update is still likely. Need confirmation.